Eylea 8 mg is the first and only anti-vascular endothelial growth factor (VEGF) treatment in the EU with treatment intervals of up to 6 months for both patients with nAMD and DME
Review will evaluate effectiveness in treating alcohol withdrawal syndrome and supporting abstinence, as well as measures to mitigate risk of abuse
The approval is based on a comprehensive package of analytical, nonclinical, and clinical data
The inspection concluded with zero Form 483 observations
Prucalopride Tablets are bioequivalent to Motegrity Tablets, 1 mg and 2 mg, of Takeda Pharmaceuticals USA
Viatel bioresorbable polymers are increasingly used in dental and orthopedic implants
Changhua site meets international regulatory standards for global medical applications
J B Chemicals and Pharmaceuticals receives ANDA approval for Amitriptyline Hydrochloride Tablets from USFDA
Prucalopride Tablets are indicated for the treatment of chronic idiopathic constipation in adults
This collaboration ensures that patients receive comprehensive care, including emotional and psychological support throughout their fertility journey
Subscribe To Our Newsletter & Stay Updated
